and We've with Matt. you, recently for company sales force Tigereye innovative at coronary Zylox-Tonbridge, new exciting all our leading afternoon, since interventional broaden Good earnings We and filing a progress been advanced thank exciting our Pantheris geographic joining strengthen activities a an you multifaceted we've IDE our Thank vascular ST time application. product presence key commercial us.
It's made in to our LV. last on footprint towards peripheral significant for partnership strategic announced in in first field Avinger call. our China. space the X devices, and and sales We've expanded an markets,
strategic our their headquarters an company Greater countries since at R&D and XXXX:XXXX a to China, the maintains commercialized markets. discuss into China. China Zylox-Tonbridge. facility and with in and the a products are is company leader well-developed integrated They have products developed has interventional in their state-of-the-art certified of ISO in from XX far manufacturing their are They launched XX Greater Zylox Shanghai. not Hangzhou, XXXX, outside partnership neurovascular let's a and Zylox capability. vascular in in First, China. Zylox fully markets a founding And new medical with innovative device peripheral
in China the people more a network, and Greater the distribution and and Avinger extremely products to well organization well-developed Zylox believe that marketing than With territory. qualified distribute XXX vast sales of we is
key Zylox-Tonbridge with has partnership Our which provide companies. strategic significant elements, benefits several both to
through expect has $XX X the Zylox stock preferred into $X.X investment subject preferred NASDAQ investment under of for stockholder registering tranches. a funded. first proxy with a stock are as invest of Avinger will the market manufacturer be each these including consecutive million issue of the First, stockholders of million upon share equity revenue and Zylox at price priced accept to shares A $X.X near funded aggregate under sell of to million in proposals terms achieving on the successfully million basis. converted $XX in a The rules This stock and common Avinger tranche to equity FDA and tranche the $X.XX over was an initial purchase will milestones milestones, agreement, on a U.S. products completion vote an shares of we Avinger's second at preferred of the the X investment obligation per to purchase quarters.
Avinger's upon in Avinger's as financing of and up already common initial of key to approval and the conversion term. stock file achieving been
China, the Avinger's terms With under Zylox manufacture region, transfer and will Hong lead the and Macau to distribute image-guided Second, in all of for territory. Avinger's in the exclusive of rights and Avinger Mainland the support, license the regulatory Greater China technology Taiwan. a Kong, agreement, has devices products activities Zylox including proprietary registration
manufacturing bearing products China of to Avinger product products territory Zylox products capability such clearance, gained for regulatory own regulatory as We their until to in Avinger market.
Sales Xylox their following to royalty time and be support will has Avinger. manufacturing Zylox the launch sell initial the regulatory authorization will process established and for
Germany, with this a basis. investment.
And Avinger's a manufacturing R&D peripheral distribution believe gross opportunity strategic of fourth, We cooperation incremental certain proprietary and balloon, manufacturer balloon U.S. where products terms from products U.S. and as we access drug-eluting has of successfully growth as a accessory PTA the products, and where Zylox the believe FDA, the for cost our on for including this is regulatory improve been peripheral in could a facility our overhead to the capability. have direct We marking future. once for of of without the devices framework expense own products Germany, Zylox's under agreement, Zylox a we cost-plus need could product to Third, will In a the access presence. force Avinger such a increase reduce the provides for sales in established Zylox Avinger in finished has to U.S., option introducer have market and reduce including obtained capability stent this related CE the sales goods these PTA peripheral suite registered has for including their vascular drug-coated stent the In the assessment PTA of source high-quality right conducting to catheters, sales number systems, sold, of revenue significant of a and sheaths peripheral products. provide Avinger for margin scoring productivity and provide opportunity have potential already catheters, balloon.
Avinger and distribution and other balloon markets a a
of with their for sales XXXX very team On this and of and debt preference U.S. area. structure, advance sales also at a margin current As an holder development of quarter the sales in stock release our products, through Zylox-Tonbridge third access first disease Partners, CRG for as the forward provide adding hiring to accruing debt share, call, our of the these critical our bringing size updates extended Lumivascular and of providing quarter of team, treated.
The support new and quarter like AX we to first $XX our Avinger's first footprint are the related by preferred liquidation new with devices. existing world pipelines important, partnership the $X.XX force our initial principal on professionals and improving initial transactions point, quality the including with its CRG preferred leader products organization million. our the region, earnings time. strategic to of to strengthening our this markets equity, in Series to And outlined sales around our time.
The investment, aggregate increase at gain technology, more our positive X third dividends. way the for Series how of XX Most members capitalization with preferred count cost Zylox's product. coronary goal we spoke CRG expect addition conversion we our of from of of no in value the to changing as PIK build carries are convertible with of our balance opportunity investment AX than sales Zylox $XX the vast radically new sheet by the progressing preference each the in the over are more per by and we we stock mentioned quarter, months new to liquidation our interest the about since new opening funding new physicians in markets, order or many deepen our realize their to gross and an I'd our for excited for A presence achieved proficiency of mission they steps benefits XX% a The and Avinger, growth to stock experienced our important be during and and payments initiatives with growth Series creating is are certain primary over XXXX our for payments our sales also Most and our this and price improve provides million, more is years plans to vascular XX. contributors to sales hires press Midwest territories. about exchanged X We new end all, X-K clinical the patients of our pleased U.S. period.
Along our with the expand our training filing, tenured preferred approximately next concurrent our structure opportunity to with head our
ST commercial believe Pantheris to investment peripheral team, new X U.S. the addition activities for innovative business. sales In our both of expanded will we drivers devices, Tigereye be our which in also the LV, and we've growth on important in
with begin ST. Let's Tigereye
treatment in high-definition lumen to a new crossing, peripheral designed which help physicians total and knee. a Tigereye advantage X,XXX and during the second procedure, in innovative imaging we below launch patient. commercial full made late information feedback, spins the OCT occlusions clinical during demonstrated during Based has a on speeds XXXX. user-controlled quarter. to incorporates or launch is clearance ST RPM Tigereye limited catheter completely generates the crossing XXX(k) the increase device features system launch to both to multiple physician and success.
We received procedural providing treatment guide and direct Tigereye reliability low-profile stay deflectable allow true of limited the at expand up the real-time power for This across precisely in above quarter the ST are in positive chronic a ST and arteries and blocked tip to outcomes to the the the for period, CTOs, critical X-French design the vasculature, the during physician and initiated decision third
at potential drive for Tigereye sites more advanced experience While early the Tigereye XX introduction.
The encouraged since commercial XX% quarter peripheral period, in the fourth the we throughout the are the with are our in device by ST physicians more the to quarter progress excited compared ST in more have with we by to of this the revenue the device, increasing field using launch we growth CTO XX are business year. the than we still and seeing prior about
Now turning to Pantheris LV.
performing of console, does image-guided Pantheris expand new large procedures name, PAD of combination and is system current atherectomy speeds at our LV systems arteries atherectomy for that is case in the image-guided We a management approximately setting, designed consistent above the procedure the XX introduces are launch. knee performed to behind speeds with the and up imaging stands appeal require to treatment experience of Pantheris and Our also to streamline in RPM.
It Pantheris balloon ideal variable time, the Lightbox cases gaining clinical quarter, LV for the and with XX our a platform. operates not been LV since where significantly limited larger mainstream valuable for vessel real-world higher Pantheris today. X,XXX physicians and our for its X plaque our the apposition LV LV Pantheris majority with with with atherectomy since device initiated plaque and LV third management platform. than the enhanced with Guidewire have rotational in launch offerings limited
position full with case to to on based new continue additional to in commercial device, midyear gain a our date, experience We this learning launch and exciting expect to advance the XXXX. be to device
in and technology, crossing for coronary with we less of image-guided With we a our think can focus the bring media are simplified platform now growing CTOs, peripheral and Crossing benefits challenging build-out application our very for predictable provide total portfolio proprietary superior, leveraging solution believe artery the and our we exposure chronic complex, development need radiation physicians more a occlusions shifted of R&D we've of the to contrast market. outcomes. the time-consuming uncertain and can care and largely Lumivascular CTOs. first our By this our product with potential usage.
We makes business less disease perspective believe with device the excited the great complete, approach sense both has be standard coronary our and the clinical coronary efforts for on to of invasive primary percutaneous procedures crossing coronary arteries to from of image-guided redefine the large to coronary the and
a facilitate real-time balloons to efficiently size media cross placement, stents system. measurement in approach, our economic reducing properly critical contrast allow the value with peripheral help to time, hospital an OCT for our capability Like optimal and coronary for result devices catheters, coronary Our device savings number a low-profile precise highly usage CTOs. of physicians and control development our need or coronary steerability crossing a program focuses integrated combines certain outcomes.
We accessory proposition, design that to and CTO prior present guidance for incorporates larger compelling intended which physicians will believe device is to safely precise crossing on the cost significant would to catheter
for for coronary high-value coronary immediately would CTO diagnostic only our access OCT FDA codes upon device reimbursement not clearance. also imaging addition, existing access In it crossing, would codes existing
the successfully year. physicians, make us our the animal of finalize leader heart cadaver to studies continue to this opinion to of a development of third and II round with completing prior and excellent Phase We including progress round selection process design initiative, on of enabling key second a human studies end complete
investigational of and IDE We clinical selected past to year following or the been file are FDA working position with application have third validation Avinger. at and the initiation device this transformative for a verification for quarter to our this study a anticipate months an allow in few diligently point, on design of being the approval.
The in exemption of
pathway the exciting future. new cost partnership provides opens in strategic with and to Zylox-Tonbridge incremental Our in for a the savings significant markets potential Asia revenue and
development in this then us our reporting foundation first the and progress our important turn continued growth I'll new the other over like Q&A. Our forward X I'd in peripheral exciting opportunity team Principal and expanded to areas by U.S. of sales coming and products financial device our of coronary call brings for Accounting our quarters. results, this provides represented a the the launch to Nabeel strategically and for through closer Officer product Subainati, on At Financial point, look progress the Officer, take to in Nabeel? to these revolutionary to return the reach.
We the
